RNA-based therapies have typically been described as programmable medicines, so maybe it’s not too shocking {that a} biotech firm would adapt strategies and processes from the tech business to develop and manufacture messenger RNA medicine. Nutcracker Therapeutics, a biotech firm whose strategy to mRNA medicines borrows from the semiconductor business, has raised $167 million to develop its drug pipeline and refine its manufacturing expertise.
Emeryville, California-based Nutcracker says its RNA manufacturing expertise combines biochemistry with {hardware} and software program to make its mRNA therapies on single-use, semiconductor-like “biochips.” The corporate notes that mRNA just isn’t inherently bioavailable, that means there are limitations to how these molecules are absorbed and utilized by the physique. Therapies primarily based on mRNA require supply autos to get them to their locations. Nutcracker says its has developed a library of proprietary supply automobile compositions. The corporate additionally has proprietary processes for mixing and formulating mRNA and supply autos to yield its mRNA medicines.
The Nutcracker system is enclosed and automatic, operating a producing course of that’s managed by software program. The corporate additionally says its expertise can scale up as a remedy makes progress, enabling manufacturing from the invention stage throughout scientific testing and commercialization. The corporate additionally says its expertise can doubtlessly cut back the prices and cycle instances of RNA therapeutic growth.
Nutcracker has not disclosed any particulars about its drug pipeline, aside from to say that it’s growing therapies for most cancers.
“The current success of the mRNA vaccines for COVID-19 has introduced newfound vitality round the usage of RNA as a therapeutic device,” Igor Khandros, co-founder and CEO of Nutcracker Therapeutics, mentioned in a ready assertion. “As a consequence, we’ve an unparalleled alternative to convey this rising class of medicines to deal with sufferers affected by very complicated ailments.”
The Collection C spherical of funding introduced Monday was led by ARCH Enterprise Companions. Nutcracker final raised cash in 2020, a $60 million Collection B spherical of funding that was additionally led by ARCH.
Picture by Flickr person Instrument Dude8mm by way of a Artistic Commons license
0 Comments